Key result
Serum salusin-beta levels were suggested to play a role as a biomarker for the evaluation of coronary slow flow in the absence of significant coronary artery disease.
This letter highlights the potential role of serum salusin-beta as a biomarker for coronary slow flow and its established association with the development and progression of atherosclerosis.
To the Editor, We have read the paper written by Akyz et al. (1) titled "Relationship of serum salusin beta levels with coronary slow flow" with great interest. In this research, the authors compared serum salusin- levels between two patient groups, those with normal coronary arteries and those with coronary slow flow (CSF) pattern in the absence of significant coronary artery disease. They concluded that serum salusin- levels could play a role as a biomarker for the evaluation of CSF. In previous studies, salusin- has been reported to be related to the development and progression of atherosclerosis, and it has been shown that the circulating levels are high in patients with documented atherosclerosis (2, 3).
No takes yet. Share an insight, caveat, or question.
Si̇nan Akıncı (2019) conducted a letter in Coronary slow flow. Serum salusin-beta levels vs. Normal coronary arteries was evaluated on Coronary slow flow pattern. Serum salusin-beta levels were suggested to play a role as a biomarker for the evaluation of coronary slow flow in the absence of significant coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: